The Dexcom G5 Mobile CGM System - A classic diabetes wearable that still anchors Dexcom’s sensor lineup

Dexcom G5 Mobile CGM System keeps glucose data flowing every five minutes for people living with diabetes who still rely on this legacy sensor platform. Anyone holding Dexcom Inc. stock (NASDAQ: DXCM, ISIN US2521311074) should know this product.

By Julian Reed, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 12:52 AM ET. Details in the imprint.

Dexcom G5 Mobile CGM System sits like a small white patch on the back of your arm, quietly streaming glucose readings to your phone while you’re trying to sleep through a humid summer night. For many long-term Dexcom users, this legacy wearable is still the daily routine. The plastic housing scratches a little under a T-shirt, but its data feed is familiar, trusted, and very much alive in the market.

What keeps Dexcom G5 relevant

Dexcom Inc. positions the G5 Mobile as a continuous glucose monitoring system that delivers readings every five minutes and can share data with up to five followers for remote monitoring. Official Dexcom product information That cadence is slower than the newest sensors, but for many people with diabetes the combination of alerts and sharing features remains enough to manage their day-to-day risk.

Unlike Dexcom’s G7, the G5 Mobile uses a separate transmitter that snaps into a disposable sensor inserted under the skin, typically on the abdomen for adults or upper buttocks for children. Dexcom FAQ details Each sensor is approved for up to seven days of wear, while the transmitter is designed to last for about three months of continuous use before replacement. Clinical evaluation of Dexcom G5

US approval and legacy users

The Dexcom G5 Mobile was the first Dexcom system to receive FDA approval for making diabetes treatment decisions without confirmatory fingersticks, a milestone cleared in 2016. FDA approval announcement That step brought G5 firmly into US endocrinology offices and laid the groundwork for insurers to reimburse CGM more broadly.

In a clinical assessment, researchers reported mean absolute relative difference (MARD) values around 9.0 to 10.7 percent for Dexcom G5 in adults, indicating solid accuracy for day-to-day management compared with capillary glucose testing. Accuracy study on G5 That might not match newer sensors, but for many longtime users, the familiarity of the device matters at least as much as raw metrics.

How Dexcom G5 works day to day

From a user’s view, Dexcom G5 begins with a sensor insertion using a spring-loaded applicator, which places a tiny flexible filament under the skin where interstitial fluid can be measured. Once the transmitter clicks into place, the system starts a two-hour warm-up period before displaying glucose data. How G5 works

On the phone side, the Dexcom G5 Mobile app shows a colorful graph of your glucose curve, numeric values, arrows signaling whether levels are rising or falling, and customizable alerts for highs and lows. G5 overview Lying in bed, you can watch the line glide across the screen and decide whether to grab juice or insulin based on the trend rather than a single static reading.

Compatibility with pumps and apps

Dexcom G5 integrates with selected insulin pump systems and digital health platforms, although new integrations increasingly favor Dexcom’s newer sensors. For example, historical compatibility has included certain Tandem insulin pumps before many users moved toward G6 and G7 pairings. Tandem connectivity page

From a developer perspective, Dexcom has offered data interfaces that allow streaming CGM data into broader diabetes management platforms, though G5-specific tooling is now overshadowed by newer APIs. Still, for people who have built their routines around G5, the old integration pathways can keep automated insulin dosing scripts and dashboards running.

Insurance coverage and pricing in the US

In the US, Dexcom G5 Mobile has been covered by many major insurers and Medicare for eligible patients, especially those with intensive insulin therapy needs. CMS CGM coverage Commercial payers often reimburse sensors and transmitters through pharmacy or durable medical equipment channels, leaving patients with copays that vary widely by plan.

List prices for Dexcom sensors and transmitters are not always published in a straightforward way, but US pharmacies and distributors often cite total monthly costs in the low hundreds of dollars before insurance, depending on whether you count both sensors and transmitters. People who have stuck with G5 tend to be those whose coverage still recognizes the system and whose clinicians have not insisted on a switch.

Real-world experience and voices

On diabetes forums, you can find posts from users describing the feel of the Dexcom G5 transmitter housing under clothing and comparing the adhesive’s stickiness over seven days. Some praise the familiar alarm sounds; others complain about occasional sensor dropouts, especially during exercise and sweating. These human stories give texture to what can otherwise look like a sterile medical device.

Kevin Sayer, Dexcom’s longtime CEO, has repeatedly emphasized in earnings calls that the company continues supporting existing users even as it redirects most innovation toward current-generation sensors like G7. CNBC interview with Kevin Sayer That balancing act between legacy and new technology is visible in how G5 remains documented and supported even as marketing spotlights shift.

Safety, accuracy and limitations

Clinicians generally regard Dexcom G5 as accurate enough for insulin dosing and hypoglycemia prevention, but they also warn patients about limitations: lag between blood and interstitial readings, the impact of compression on readings when lying on the sensor, and occasional calibration needs. ADA guide on CGM

For people who are sensitive to adhesives, G5’s sensor tape can cause skin irritation or redness after a few days. Dermatology advice often includes barrier films, alternative tape patterns, or rotating insertion sites. In practical terms, the feel and look of the device on the skin remain part of the trade-off between constant data and bodily comfort.

Why G5 still matters for Dexcom

From Dexcom’s perspective, the G5 Mobile system is part of a long-term installed base that continues to generate cartridge-like revenue. Sensors and transmitters translate into recurring sales, and even if new prescriptions lean toward G6 and G7, legacy users can represent stable, predictable demand streams over time.

For US retail investors, the G5 story is less about headline innovation and more about installed base economics. In glucose monitoring, old products rarely vanish overnight; they fade slowly as reimbursement policies, clinical practice, and consumer preference move. Watching how quickly or slowly G5 utilization declines can offer one concrete datapoint on Dexcom’s transition pace toward its latest technology.

Company context and stock

Dexcom Inc. built its business around continuous glucose monitoring for people with diabetes, starting with early wired sensors and evolving toward smartphone-connected wearables like G5, then newer G6 and G7 lines. Dexcom annual report Each generation layers more convenience and data clarity, but legacy platforms such as G5 Mobile remain part of the narrative because of long replacement cycles in healthcare.

Dexcom stock (NASDAQ: DXCM, ISIN US2521311074) reflects that portfolio-based reality, with G5 contributing legacy sensor revenue while the company’s valuation increasingly leans on adoption of newer CGM systems and expansion into broader metabolic monitoring.

Dexcom G5 Mobile CGM System at a glance

• Product: Dexcom G5 Mobile CGM System
• Manufacturer: Dexcom Inc.
• Category: Classics / Longsellers continuous glucose monitor
• Launch: Initial FDA approval in 2016 for treatment decisions without fingersticks
• MSRP / Price: Typically low hundreds of US dollars per month before insurance for sensors and transmitter, varying by pharmacy and plan
• Availability: Available in the US and other markets as a legacy CGM system, with support focused on existing users
• Target audience: People with diabetes requiring continuous glucose data, especially intensive insulin users whose routines are built around Dexcom G5
• Standout / USP: Legacy CGM that pioneered FDA-approved non-adjunctive use, with remote sharing and a familiar sensor-transmitter format for long-term users

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.